Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial from Gilead.
The ALLIANCE trial from Gilead is investigating the triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) among treatment-naïve persons living with comorbid HIV/hepatitis B virus (HBV). Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is the trial’s principal investigator.
Transcript
Can you discuss how the ALLIANCE trial addresses HIV/HBV coinfection overlapping risk factors and transmission patterns?
The literature shows a risk factor mainly from men having sex with men and intravenous drug users. In hep B, the main transmission is from the breath; [transmission] from sexual activity is very rare, but we have seen much higher [rates] among men having sex with men. For HIV and hepatitis B, they usually have a high hepatitis B, D, and A viral load. If you have such a high viral load, you can transmit the virus to others really easily like with HIV. I think we should use the term “treatment as prevention” as well. Hepatitis B has a vaccine to prevent infection, but in some groups, the vaccine doesn’t work or it doesn’t work quite well.
For this study, we know that the HIV suppression is very high for both TDF and TAF—and this is good for HIV. Even they have such high rates of HIV suppression, when you look at the hepatitis B, it’s only 60% for TAF and 40% for TDF. So there are some subpopulations that have [suboptimal] hepatitis B treatment, but we need longer follow-up to see whether the suppression will be higher on this or not.
For me, I think if we treat the patient so we can prevent transmission of this virus to others, if we use the most effective drug, then you can lower the viruses quicker.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More